LumiThera, Inc. Inc. have announced their recent merger of Diopsys. LumiThera are a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease. With this acquisition, they find themselves merging with a leader in modern visual electrophysiology medical devices. "We are strong believers of treating degenerative disease early to slow the progression of vision-threatening disease. The synergy of these technologies makes sense on many levels and could optimize Valeda treatments" Clark Tedford, LumiThera, Inc. CEO.
In other news, Alcon previously entered the #glaucoma treatment market, but had to withdraw their product, CyPass Micro-Stent from the market due to safety concerns. Now they have found a new glaucoma treatment to acquire; Hydrus Microstent by Ivantis, Inc. The Hydrus device was approved by the FDA in 2018 and is about the size of an eyelash. It is implanted in Schlemm’s canal in a minimally invasive surgical procedure. In a five-year study of the Hydrus Microstent, patients who received the device experienced a 60% reduction in the need for secondary invasive glaucoma surgeries. “Our global commercial footprint and development capabilities make us well positioned to build on the success of Ivantis and help even more patients see brilliantly with Hydrus Microstent.” David Endicott, Alcon CEO.
Vision Executives are pleased to announce that we have reached a LinkedIn milestone of 1000 followers in our first 8 months of business. We are hugely grateful to the numerous candidates and clients that have worked with us and supported us during this time.
This means combined with James Pickering's personal connections, which he has built over the last 5 years, we have a combined eyecare network of over 6000+ professionals across 6 continents.
We aim to continue expanding our network in order for us to achieve our company vision of contributing positively to the community which makes the eyecare industry great, as we already have done with our fundraising effort for World Sight Day. Thank you for being a part of this network and helping us achieve our vision.
Keep your eyes peeled for another major announcement coming later this week!
A couple of weeks ago we wrote of some promising presbyopia updates, including Allergan (an AbbVie company). Allergan have now announced the FDA approval of Vuity. This the first eyedrop for the treatment of presbyopia to have been approved by the FDA. It is a daily prescription eyedrop which can work in as quickly as 15 minutes and last up to 6 hours. "We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia” Michael Severino, MD, vice chairman and president, AbbVie.
LENZ Therapeutics is working on eyedrops which will contain aceclidine, it is hoped aceclidine will create a pinhole effect as a miotic. It has shown improvements in their recent phase 2 trial.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.